Hearing impairment amongst people with Osteogenesis Imperfecta in Germany
- PMID: 39333311
- PMCID: PMC11805764
- DOI: 10.1007/s00405-024-08983-5
Hearing impairment amongst people with Osteogenesis Imperfecta in Germany
Abstract
Introduction: Hearing impairment concerns a relevant percentage of individuals with Osteogenesis Imperfecta (OI). When looking at the current literature, the percentage of affected individuals with OI varies greatly from 32 to 58% of patients having mild OI and 21% to 27% of patients having moderate to severe OI. Little is known about the German population with OI.
Method: The goal of this study was to detect how many patients with OI, who visited the annual meeting of the German Association for Osteogenesis Imperfecta in 2023, proved to have a hearing impairment. In this prospective, cross-sectional study, each included individual obtained ear microscopy, audiometry, stapedius reflexes, tympanometry, and OAEs. Furthermore, each patient was asked a set of questions concerning the medical history.
Results: Of the included patients, 33% had hearing impairment. A significant difference was found for the mean air-bone gap (ABG) as well as the hearing threshold of the right ears. The difference was found between OI type III and IV (p = 0.0127) for the mean ABG and OI type I and IV (p = 0.0138) as well as III and IV (p = 0.0281) for the hearing threshold. Spearman's rank correlation showed a high correlation between age and hearing threshold. Of the patients between 40 and 50 years old, 56% had hearing loss.
Conclusion: Hearing loss in individuals with OI is still a relevant problem, especially age-related in OI type I. Audiometry should be performed at least when individuals experience subjective hearing loss. The implementation of a screening starting at 40 years should be discussed and studied.
Keywords: Auditory system; Hearing impairment; Hearing loss; Osteogenesis imperfecta.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no conflict of interest. The authors have no relevant financial or non-financial interests to disclose. Institutional review board statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of University Hospital, LMU Munich (protocol code 22–0357 and date of approval 17.05.2022). Informed consent statement: Informed consent was obtained from all subjects involved in the study.
Figures
References
-
- Hoyer-Kuhn JB-SH, Blickheuser R, Deimling U, Stücker R, Wirth T, Wolf J, Wollinsky KH & Semler O (2016) Diagnostik und Therapie der Osteogenesis imperfecta - Konsensus-Statement der 30. Jahrestagung 2014 der Deutschen Gesellschaft für Osteogenesis imperfecta Betroffene e.V. Monatsschrift Kinderheilkunde. 165:333–346
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
